Objectives: The objective of this study was to identify optimal renal dose adjustments for 2 g of cefepime every 8 h as a 3 h infusion where the probability of target attainment was optimized and drug accumulation was minimal.
Introduction
Prolongation of the infusion time has been employed as a means to enhance the pharmacodynamic profile of many b-lactam antibiotics, including cefepime. 1 -3 Studies have shown that the probability of target attainment (PTA) profile of maximal-dose cefepime (2 g every 8 h) can be substantially improved by infusing it over 3 h relative to 30 min. 3, 4 Like most b-lactams, cefepime is primarily excreted by the kidneys and dose alterations are required for patients with varying degrees of renal function. 5, 6 Thus, successful implementation of a pharmacodynamic dose optimization strategy for cefepime requires an understanding of the appropriate dose adjustment schemes across varying degrees of renal function. The objective of this study was to identify optimal renal dose adjustments for 2 g of cefepime every 8 h as a 3 h infusion where the PTA was optimized and drug accumulation was minimal.
Methods
Cefepime exposure profiles were estimated from a previously published open two-compartment population pharmacokinetic model of 36 patients with varying degrees of renal function who received cefepime for a presumed or documented infection. 5 In this model, cefepime clearance was expressed as a proportion of CL CR plus an intercept term (non-renal clearance estimate). This pharmacokinetic model was selected for the Monte Carlo simulation studies for several reasons. First, it was developed in the largest study of actual patients with varying degrees of renal function performed to date. Of the 36 patients in the study, 12 had a CL CR .100 mL/min, 12 had a CL CR between 60 and 100 mL/min, and 12 had a CL CR between 11 and 59 mL/min. Second, it fitted the data well based on the model diagnostic provided; the plots of predicted versus observed plasma concentrations after the Bayesian step showed slopes and intercepts very close to the ideal values of 1.0 and 0.0, respectively. Third, the population pharmacokinetic estimates for the selected model, most importantly clearance, were highly concordant with another published # The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2015; 70: 877 -881 doi:10.1093/jac/dku435 Advance Access publication 6 November 2014 cefepime population pharmacokinetic model that was similarly derived in 32 hospitalized patients with varying degrees of renal function. 6 Embedded with this population pharmacokinetic model, 5 a series of 5000-subject Monte Carlo simulations were performed using the ADAPT 5 package. 7 A population simulation without process noise option was utilized and log-normal distributions of pharmacokinetic parameters were selected based on its ability to recreate the original mean parameter vector and associated distribution. To reflect unbound drug concentrations, cefepime data were adjusted for 20% protein binding. 8 Simulations were performed for 3 h infusions of 2 g every 6, 8, 12 and 24 h. To assess exposure profiles across various levels of renal function, the estimated CL CR was fixed at values between 20 and 150 mL/min at 10 mL/min intervals. 9, 10 For each regimen examined, the fraction of simulated subjects who achieved free drug concentrations in excess of the MIC for ≥60% of the dosing interval (60% fT . MIC) 4,11 -13 for MIC values between 0.25 and 32 mg/L at the various CL CR levels was determined. As sensitivity analyses, we examined the probability of achieving 50% and 75% fT . MIC. Since early appropriate therapy has been implicated as a major factor in the outcomes of patients with serious infections, 14, 15 this analysis focused on PTA at 24 h.
Given the lack of a clearly defined exposure-toxicity threshold derived in a large dataset, we chose to compare cumulative drug exposure (AUC 24 -48 ) between the various dose-adjusted regimens to describe the degree of drug accumulation associated with a given dose-adjustment scheme. The AUC 24 -48 was determined for each simulated dosing regimen at each CL CR stratum. To assess the maximum degree of cefepime exposure for each potential renal dose alteration scheme (i.e. extending the dosing interval from 8 to 12 h and from 12 to 24 h, and shortening the dosing interval from 8 to 6 h), we computed the ratio of the AUC 24 -48 at the point of maximal exposure for a given cefepime renal dose alteration scheme relative to the AUC 24 -48 of the reference exposure regimen (2 g every 8 h over 3 h at a CL CR of 100 mL/min). 9, 10 We designated this Zasowski et al.
as the 'reference' as this regimen at this level of CL CR has been found to be well tolerated and safe. 16 
Results
Results of the PTA analyses for the parent and dose-adjusted regimens are summarized in Table 1 . For the reference regimen, the probability of achieving 60% fT .MIC exceeded 90% for the full range of MIC values (≤8 mg/L) considered susceptible by EUCAST 17 and CLSI 18 up to a CL CR of 120 mL/min. To achieve adequate PTA for MIC values ≥8 mg/L at CL CR values ≥130 mL/min, 2 g every 6 h (3 h infusion) was required. When the interval was lengthened to 12 h, PTA was 90% at a CL CR of 70 mL/min at an MIC of 8 mg/L and ≤70% for MIC ≥16 mg/L. In slight contrast, the PTA profile for this regimen exceeded 90% at an MIC of 8 mg/L when CL CR was fixed at 60 mL/min but was ,80% when the MIC value was 16 or 32 mg/L. Further extension of the dose interval to 24 h produced suitable PTA profiles at a CL CR of 20 mL/min but resulted in sub-optimal PTA for MIC values ≥8 mg/L when CL CR was 30 mL/min. Results of the sensitivity analyses (50% and 75% fT. MIC) were highly consistent with the primary PTA analysis.
Overall, the AUC 24 -48 values were relatively comparable for the various renal adjustment regimens across the CL CR strata ( Table 2 ). For the augmented renal dose alteration scheme (2 g every 6 h), the median AUC 24 -48 at a CL CR of 120 mL/min was 967 mg . h/L, which is similar to that of the reference exposure; all subjects had an AUC 24 -48 exposure ratio between 1.10 and 1.23 (Figure 1a) . For the first proposed renal dose adjustment threshold, the median AUC 24 -48 at the point of maximal exposure (2 g every 8 h at a CL CR of 60 mL/min) was 1210 mg . h/L and there were no subjects with an AUC 24 -48 exposure ratio in excess of 1.64 at this dosing cut-off (Figure 1b) . Figure 1(c) displays the distribution of AUC 24 -48 exposure ratios for the second renal reduction scheme (2 g every 12 h) at the CL CR breakpoint of 20 mL/min (point of maximal exposure). While some subjects experienced an AUC 24 -48 exposure ratio .3, the majority of subjects had a ratio ,2.5, and the median AUC 24 -48 was 1475 mg . h/L. If the dose adjustment was made at a CL CR breakpoint of 30 mL/min rather than 20 mL/min, the median (IQR) AUC 24 -48 and median AUC 24 -48 
Discussion
Although the pharmacodynamics of extended-infusion cefepime have been described previously, 2 -5 this is the first known analysis specifically designed to determine the optimal pharmacokinetic/ pharmacodynamic renal dose adjustment schemes for extendedinfusion cefepime. Using a recently described, innovative approach to determine the optimal pharmacokinetic/ pharmacodynamic renal dose adjustment breakpoints for timedependent antibiotics, 9, 10 there were several notable findings from these PTA analyses. The results suggest that high-dose extended-infusion cefepime should be adjusted to every 12 h at a CL CR of 60 mL/min and to every 24 h at a CL CR of 20 mL/min. The probability of achieving 60% fT .MIC for these dosing schemes exceeded 90% against MICs up to 8 mg/L. Comparison of median AUC 24 -48 values and AUC 24 -48 exposure ratios at the points of maximal exposure indicated that these dose alterations did not result in substantial drug exposure. An argument can be made for having the second dose adjustment at 30 mL/min, which is the current recommendation from the manufacturer with 30 min infusion dosing schemes, rather than 20 mL/min based on the AUC data. However, the probability of achieving 60% fT .MIC was ,90% at an MIC of 8 mg/L if the second dose alteration was made at this threshold. Since the exposuretoxicity relationship for cefepime is poorly defined, we support making the second dose adjustment at a CL CR of 20 mL/min, especially when treating Gram-negative infections with documented or suspected higher MICs, such as Pseudomonas aeruginosa. It should be noted that since no defined toxicity threshold exists, we designated the median AUC observed among patients receiving 2 g of cefepime every 8 h at CL CR of 100 mL/min as the reference or target exposure as this regimen at this level of CL CR has been shown to be well tolerated and safe. 16 Consequently, patients with renal impairment should be monitored closely due to the limited reports of cefepime-induced neurotoxicity among this patient population, including seizures. 19 The PTA analyses also indicate that a more intensive regimen of 2 g every 6 h was required when CL CR exceeded 120 mL/min. Although there are few clinical or safety data surrounding this regimen, the resulting AUC 24 -48 values were not substantially different from those of the parent regimen despite the larger daily dose. This is not the first time this phenomenon has been observed and these findings suggest dose supplementation may be required in patients with augmented renal function. 20, 21 In conclusion, our results suggest that the extended-infusion regimen of 2 g every 8 h should be adjusted to every 12 h for CL CR ≤60 mL/min and further to every 24 h for CL CR ≤20 mL/min. In addition, our findings indicate that more intensive dosing schemes (2 g every 6 h) may be required in patients with CL CR .120 mL/min. These renal dose alteration regimens yielded favourable pharmacodynamic profiles without undue drug exposure. Since our findings were based on mathematical models, they should be validated in the clinical arena. As part of the validation, the predictive performance of the cefepime pharmacokinetic model used in these analyses should be prospectively determined. In particular, the relationship between cefepime clearance and CL CR needs to be substantiated in a sufficient patient sample as this covariate will ultimately be used by clinicians to guide cefepime dosing.
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